BioXcel Therapeutics EPS
The Earnings per Share (EPS) of BioXcel Therapeutics (BTAI) as of Oct 20, 2026 is -5.73 USD. In the previous year, Earnings per Share (EPS) was -19.61 USD — a change of -70.81% (higher).
Get this data via API
Financial Data API
EPS
-5.73USD
YoY
-70.81%
Last updated:
The BioXcel Therapeutics EPS history
3 Years
10 Years
25 Years
Max
| YEAR | EPS | YoY |
|---|---|---|
| est | 1.48USD | -338.71% |
| est | -0.62USD | -21.52% |
| est | -0.79USD | -63.08% |
| est | -2.14USD | -20.74% |
| est | -2.70USD | -52.84% |
| -5.73USD | -70.81% | |
| -19.61USD | -79.84% | |
| -97.28USD | +1,547.26% | |
| -5.91USD | -90.31% | |
| -60.97USD | +13.27% | |
| -53.83USD | +88.21% | |
| -28.60USD | +45.31% | |
| -19.68USD | +278.36% | |
| -5.20USD | +145.39% | |
| -2.12USD | +3,969.33% | |
| -0.05USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioXcel Therapeutics Stock analysis
Frequently Asked Questions about BioXcel Therapeutics stock
Earnings per Share (EPS) of BioXcel Therapeutics is -5.73 USD in 2025.
Earnings per Share (EPS) of BioXcel Therapeutics changed from -19.61 USD to -5.73 USD, representing a -70.81% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Earnings per Share (EPS) BioXcel Therapeutics since 2006 – with annual values, charts, and detailed analysis.
Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.
EPS = Net Income / Shares Outstanding
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — BioXcel Therapeutics
All Key Metrics — BioXcel Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth